|
1
|
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
|
Cancer Res
|
2011
|
1.28
|
|
2
|
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis.
|
J Clin Invest
|
2002
|
1.12
|
|
3
|
Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression.
|
J Invest Dermatol
|
2003
|
1.00
|
|
4
|
Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.
|
Oncogene
|
2004
|
0.99
|
|
5
|
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
|
Mol Cancer Ther
|
2012
|
0.92
|
|
6
|
Is PDGFR an important target for E-3810?
|
J Cell Mol Med
|
2012
|
0.75
|